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OBJECTIVES: To compare the efﬁcacy of opioids in reducing
breakthrough pain within 15 min after taking the medication, in
patients with cancer. METHODS: Randomised controlled trials
investigating the efﬁcacy of opioids administered orally or intra-
nasally were identiﬁed with a systematic literature search. The
endpoint of interest was the reduction in pain intensity (pain
intensity difference (PID)) recorded on a 0–10 numeric rating
scale within 15 min after taking the medication. Outcomes of all
trials were analysed simultaneously with a Bayesian mixed treat-
ment comparison. RESULTS: In addition to one trial report on
the use of intranasal fentanyl spray (INFS), four relevant studies
were identiﬁed, allowing comparisons between INFS, oral trans-
mucosal fentanyl citrate (OTFC), fentanyl buccal tablet (FBT),
and morphine sulphate immediate release (MSIR). INFS was
more efﬁcacious than placebo: the relative treatment effect, PID
at 10 min post dosing (PID10), was 1.28 (positive values indicate
a reduction in pain), 95% Credibility Interval (CrI): 0.91;1.65.
OTFC and FBT at 15 min were also more efﬁcacious than
placebo: the relative treatment effect, PID15 (mean  95%CrI),
was 0.60 (0.11;1.09) for OTFC and 0.51 (0.29;0.73) for FBT.
MSIR displayed similar efﬁcacy to placebo: PID15 0.18
(-0.50;0.86). INFS provided a greater pain reduction after 10
min than the other interventions after 15 min. The relative treat-
ment effects of INFS (PID10) versus other treatments (PID15)
were: 0.68 (0.06;1.30) versus OTFC, 0.77 (0.34;1.20) versus
FBT and 1.10 (0.32;1.87) versus MSIR, corresponding to a prob-
ability of 98% or more of INFS being the most efﬁcacious treat-
ment. CONCLUSIONS: The current study demonstrated that in
the treatment of breakthrough pain in patients with cancer (i)
MSIR has similar efﬁcacy to placebo 15 min after dosing and (ii)
INFS is the most efﬁcacious treatment for reducing breakthrough
pain within 15 min after dosing compared with OTFC, FBT and
MSIR.
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OBJECTIVES: Using observational chronic lymphocytic leu-
kaemia (CLL) data collected by Tam et al., (2008), we compared
the treatment effect of ﬁrst line Rituximab, Fludarabine and
Cyclophosphamide (R-FC) with FC, inspecting the impact of
prognostic factors and modeling life-time health outcomes.
METHODS: Different lengths of follow-up in FC (1995–2007,
n = 108) and R-FC (1999–2007, n = 300) treated patient cohorts
was accounted for in a Cox’s proportional hazards model. The
following prognostic factors were examined for association with
treatment outcomes: age, gender, beta-2 microglobulin (b2M)
and Binet stage. The best parametric ﬁt (Weibull) was used to
extrapolate progression free survival (PFS) with 6 year median
follow-up to a 30 year time horizon, and a Markov process to
model the transition from the progressed health state to death.
Rates of death in the PFS and progressed state were based on
background mortality and CLL mortality as observed, respec-
tively. No continued beneﬁt was assumed beyond the observa-
tional period. RESULTS: Prognostic factors were evenly
distributed between treatment groups. In univariate Cox models,
age, Binet stage and b2M were conﬁrmed as prognostic factors .
For b2M, the hazard ratio (HR) was 2.41 (1.72–3.38)3 2x upper
limit normal (N) compared to <2N. Similar signiﬁcant increases
were observed in the elderly (>70 years) and patients with Binet
C stage. The treatment effect of R-FC versus FC adjusted for
b2M, binet and age (HR 0.54 (0.38–0.77), was broadly similar
to univariate estimate (HR 0.57 (0.40–0.81). Patients on R-FC
spent on average 2.5 years longer in PFS than FC patients and
experienced longer mean life expectancy (9.9 years for R-FC, 7.7
years for FC). CONCLUSIONS: The treatment beneﬁt of R-FC
over FC in this CLL observational cohort is not affected by
prognostic factors and is predicted to generate a considerable
increase in life expectancy.
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